JP2020534839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534839A5 JP2020534839A5 JP2020517553A JP2020517553A JP2020534839A5 JP 2020534839 A5 JP2020534839 A5 JP 2020534839A5 JP 2020517553 A JP2020517553 A JP 2020517553A JP 2020517553 A JP2020517553 A JP 2020517553A JP 2020534839 A5 JP2020534839 A5 JP 2020534839A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amino acid
- acid sequence
- mutant
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 40
- 238000000034 method Methods 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 14
- 108091008874 T cell receptors Proteins 0.000 claims 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 4
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 3
- 108700025694 p53 Genes Proteins 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101150111660 53 gene Proteins 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000003501 co-culture Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565464P | 2017-09-29 | 2017-09-29 | |
| US62/565,464 | 2017-09-29 | ||
| PCT/US2018/051280 WO2019067242A1 (en) | 2017-09-29 | 2018-09-17 | METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534839A JP2020534839A (ja) | 2020-12-03 |
| JP2020534839A5 true JP2020534839A5 (enExample) | 2021-10-28 |
| JP7391015B2 JP7391015B2 (ja) | 2023-12-04 |
Family
ID=63763012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517553A Active JP7391015B2 (ja) | 2017-09-29 | 2018-09-17 | Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200316121A1 (enExample) |
| EP (2) | EP4495133A3 (enExample) |
| JP (1) | JP7391015B2 (enExample) |
| KR (1) | KR102809909B1 (enExample) |
| CN (1) | CN111344394A (enExample) |
| AU (1) | AU2018342245B2 (enExample) |
| CA (1) | CA3080274A1 (enExample) |
| IL (1) | IL273516B2 (enExample) |
| SG (1) | SG11202002635RA (enExample) |
| WO (1) | WO2019067242A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| MD3551221T2 (ro) | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| WO2020264269A1 (en) * | 2019-06-27 | 2020-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| CN112390875B (zh) * | 2019-08-16 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力t细胞受体 |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| AU2021336399A1 (en) * | 2020-09-04 | 2023-05-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r273c or y220c mutations in p53 |
| CN112301088B (zh) * | 2020-10-21 | 2022-12-13 | 杭州纽安津生物科技有限公司 | 一种筛选新生抗原或新生抗原编码序列的方法 |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| JP2024509472A (ja) * | 2021-03-08 | 2024-03-01 | 大鵬薬品工業株式会社 | Ｆｇｆｒ２及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療 |
| WO2022212682A2 (en) * | 2021-03-31 | 2022-10-06 | The Johns Hopkins University | Methods and materials for targeting tumor antigens |
| EP4334340A1 (en) * | 2021-05-07 | 2024-03-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| EP4423143A4 (en) * | 2021-10-29 | 2025-10-01 | Yafei Hou | T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| WO2024131372A1 (zh) * | 2022-12-23 | 2024-06-27 | 上海市第一人民医院 | 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用 |
| AU2024277363A1 (en) * | 2023-05-25 | 2025-12-11 | Elicio Therapeutics, Inc. | Compositions containing p53 peptide amphiphiles and methods of use thereof |
| CN116970058B (zh) * | 2023-09-22 | 2023-12-15 | 成都朗谷生物科技股份有限公司 | 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用 |
| WO2025060149A1 (zh) * | 2023-09-22 | 2025-03-27 | 上海市第一人民医院 | 一种分离的tcr及其用途 |
| WO2026040998A1 (zh) * | 2024-08-20 | 2026-02-26 | 上海灵识质源生物技术有限公司 | Tp53突变体表位肽和特异性t细胞受体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2136624A1 (en) | 1992-05-26 | 1993-12-09 | Cornelis J. M. Melief | Peptides of human p53 protein for use in human t cell response inducing compositions, and human p53 protein-specific cytotoxic t-lymphocytes |
| JPH0959175A (ja) * | 1995-06-12 | 1997-03-04 | Meiji Milk Prod Co Ltd | 抗腫瘍免疫活性化剤 |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| GB2440736A (en) * | 2006-08-10 | 2008-02-13 | Medical Res Council | Crystals of mutant p53 polypeptidtes |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2924709T3 (es) | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| CN107075479A (zh) * | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| CA2964785A1 (en) * | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| SG10201913978RA (en) * | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| IL273515B2 (en) * | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
-
2018
- 2018-09-17 JP JP2020517553A patent/JP7391015B2/ja active Active
- 2018-09-17 EP EP24215129.8A patent/EP4495133A3/en active Pending
- 2018-09-17 CA CA3080274A patent/CA3080274A1/en active Pending
- 2018-09-17 EP EP18782605.2A patent/EP3688142B1/en active Active
- 2018-09-17 US US16/650,696 patent/US20200316121A1/en active Pending
- 2018-09-17 SG SG11202002635RA patent/SG11202002635RA/en unknown
- 2018-09-17 IL IL273516A patent/IL273516B2/en unknown
- 2018-09-17 KR KR1020207012343A patent/KR102809909B1/ko active Active
- 2018-09-17 AU AU2018342245A patent/AU2018342245B2/en active Active
- 2018-09-17 CN CN201880063656.4A patent/CN111344394A/zh active Pending
- 2018-09-17 WO PCT/US2018/051280 patent/WO2019067242A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273516B2 (en) | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation | |
| JP2017531640A5 (enExample) | ||
| Alizadeh et al. | IFNγ is critical for CAR T cell–mediated myeloid activation and induction of endogenous immunity | |
| KR102821381B1 (ko) | 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도 | |
| CN110612446B (zh) | 分离新抗原-特异性t细胞受体序列的方法 | |
| BR112019023076A2 (pt) | expansão de células t gama delta, composições e métodos de uso das mesmas | |
| JP2024527559A5 (enExample) | ||
| CN104159917A (zh) | 使用icos基cars增强抗肿瘤活性和car持久性 | |
| AU2014407540A1 (en) | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation | |
| CA2791975A1 (en) | Icos critically regulates the expansion and function of inflammatory human th17 cells | |
| CN113101363B (zh) | 一种环状rna疫苗及其应用 | |
| JP2023504042A5 (enExample) | ||
| Song et al. | Targeting cytokine signals to enhance γδT cell-based cancer immunotherapy | |
| JP2024540102A (ja) | 細胞を生成する方法 | |
| CN114786779A (zh) | 用于t细胞受体鉴定的组合物和方法 | |
| CN117580946A (zh) | 用于产生抗原特异性t细胞的方法 | |
| US20240216426A1 (en) | Recombinant antigen presenting cells | |
| TW202405166A (zh) | 用於活化免疫細胞之組合物及方法 | |
| Dickerson et al. | Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours | |
| US20210113617A1 (en) | Methods and compositions for th9 cell mediated cancer treatment | |
| CN117242090A (zh) | CAR T细胞疗法和IFNγ | |
| US20230036952A1 (en) | Methods of producing t cell populations using induced pluripotent stem cells | |
| HK40105281A (en) | Car t cell therapy and ifn gamma | |
| US20250073268A1 (en) | Chimeric cd40 polypeptides and methods of use in immunotherapy | |
| US20250195657A1 (en) | Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain |